Your browser is no longer supported. Please, upgrade your browser.
Settings
ORGO Organogenesis Holdings Inc. daily Stock Chart
ORGO [NASD]
Organogenesis Holdings Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own91.84% Shs Outstand92.24M Perf Week-10.63%
Market Cap651.21M Forward P/E- EPS next Y-0.26 Insider Trans- Shs Float7.51M Perf Month-13.59%
Income-64.80M PEG- EPS next Q-0.11 Inst Own0.90% Short Float0.55% Perf Quarter-61.66%
Sales193.40M P/S3.37 EPS this Y-96.80% Inst Trans64.66% Short Ratio0.33 Perf Half Y-29.75%
Book/sh0.68 P/B10.38 EPS next Y10.30% ROA-23.40% Target Price12.00 Perf Year-29.40%
Cash/sh0.23 P/C30.57 EPS next 5Y- ROE-27.40% 52W Range6.28 - 310.90 Perf YTD-30.44%
Dividend- P/FCF- EPS past 5Y- ROI-50.60% 52W High-97.73% Beta-
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin64.40% 52W Low12.42% ATR0.61
Employees700 Current Ratio1.10 Sales Q/Q19.70% Oper. Margin-27.80% RSI (14)37.65 Volatility4.96% 7.73%
OptionableNo Debt/Eq1.26 EPS Q/Q-620.30% Profit Margin-33.50% Rel Volume0.35 Prev Close7.13
ShortableNo LT Debt/Eq1.05 EarningsMar 18 AMC Payout- Avg Volume126.28K Price7.06
Recom1.00 SMA20-11.52% SMA50-13.76% SMA200-43.99% Volume44,079 Change-0.98%
Apr-17-19Initiated Oppenheimer Outperform $11
Apr-11-19Initiated SunTrust Buy $11
Apr-02-19 07:30AM  Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2019 Financial Results on May 10, 2019 GlobeNewswire
Apr-01-19 08:30AM  Organogenesis Compliant With Nasdaq Listing Criteria GlobeNewswire
Mar-18-19 04:05PM  Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results GlobeNewswire
Mar-14-19 04:05PM  Organogenesis Holdings Inc. Announces New $100 Million Credit Agreement with Silicon Valley Bank and MidCap Financial PR Newswire
Mar-12-19 09:00AM  Organogenesis Holdings Inc. Announces ReNu® Clinical Trial Results at AAOS 2019 Annual Meeting GlobeNewswire
Mar-11-19 07:30AM  Organogenesis Holdings Inc. to Present at Oppenheimers 29th Annual Healthcare Conference GlobeNewswire +38.08%
Mar-04-19 09:00AM  New Study Shows PuraPly® Antimicrobial Positively Impacts Course of Healing Across Variety of Wound Types GlobeNewswire
Feb-25-19 08:00AM  Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 18, 2019 GlobeNewswire
Jan-24-19 10:00AM  Organogenesis to Sponsor Jan. 30 Webinar, Chronic Wounds and Biofilms: Advancing Assessment and Treatment, Featuring Dr. Gregory Schultz GlobeNewswire -8.13%
Jan-07-19 05:54PM  Organogenesis Holdings Inc. Receives Positive Nasdaq Listing Determination PR Newswire
04:15PM  Nasdaq Scheduled Resumption in Organogenesis Holdings Inc. GlobeNewswire
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.